BACKGROUND: Obesity could attenuate diuretic effectiveness in treatment of acute decompensated heart failure (HF). METHODS AND RESULTS: The DOSE trial randomized 308 subjects with acute HF to low- versus high-intensification intravenous diuretic therapy. We tested for statistical interactions between obesity and dosing strategy across clinical end points. After 72 hours of treatment, obese subjects (body mass index >30 kg/m(2); n = 173) had greater volume loss than nonobese subjects (n = 119) but similar improvements in dyspnea and freedom from congestion. Both groups had greater fluid loss with high-intensification treatment. Obese subjects had a higher incidence of worsening renal function (WRF) at 72 hours with low-intensification treatment, compared with nonobese subjects. In contrast, nonobese and obese subjects had similar incidence of WRF with high-intensification treatment. There were no differences between obese and nonobese subjects in time to discharge and 60-day freedom from death, emergency department visit, or rehospitalization. CONCLUSIONS: The incidence of WRF was greater in obese than in nonobese subjects with low-intensification treatment. However, the frequency of WRF was equivalent in obese and nonobese subjects with high-intensification treatment. Additional studies are needed to assess whether obese patients with acute HF benefit from an initial high-intensification treatment strategy. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:Obesity could attenuate diuretic effectiveness in treatment of acute decompensated heart failure (HF). METHODS AND RESULTS: The DOSE trial randomized 308 subjects with acute HF to low- versus high-intensification intravenous diuretic therapy. We tested for statistical interactions between obesity and dosing strategy across clinical end points. After 72 hours of treatment, obese subjects (body mass index >30 kg/m(2); n = 173) had greater volume loss than nonobese subjects (n = 119) but similar improvements in dyspnea and freedom from congestion. Both groups had greater fluid loss with high-intensification treatment. Obese subjects had a higher incidence of worsening renal function (WRF) at 72 hours with low-intensification treatment, compared with nonobese subjects. In contrast, nonobese and obese subjects had similar incidence of WRF with high-intensification treatment. There were no differences between obese and nonobese subjects in time to discharge and 60-day freedom from death, emergency department visit, or rehospitalization. CONCLUSIONS: The incidence of WRF was greater in obese than in nonobese subjects with low-intensification treatment. However, the frequency of WRF was equivalent in obese and nonobese subjects with high-intensification treatment. Additional studies are needed to assess whether obesepatients with acute HF benefit from an initial high-intensification treatment strategy. Published by Elsevier Inc.
Authors: Jeffrey M Testani; Thomas P Cappola; Colleen M Brensinger; Richard P Shannon; Stephen E Kimmel Journal: J Am Coll Cardiol Date: 2011-07-19 Impact factor: 24.094
Authors: Apoor S Gami; Dave O Hodge; Regina M Herges; Eric J Olson; Jiri Nykodym; Tomas Kara; Virend K Somers Journal: J Am Coll Cardiol Date: 2007-01-22 Impact factor: 24.094
Authors: Gregg C Fonarow; Preethi Srikanthan; Maria Rosa Costanzo; Guillermo B Cintron; Margarita Lopatin Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Liviu Klein; Christopher M O'Connor; Jeffrey D Leimberger; Wendy Gattis-Stough; Ileana L Piña; G Michael Felker; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade Journal: Circulation Date: 2005-05-02 Impact factor: 29.690
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: S G Lakoski; M Cushman; D S Siscovick; R S Blumenthal; W Palmas; G Burke; D M Herrington Journal: J Hum Hypertens Date: 2010-10-14 Impact factor: 3.012
Authors: Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Rebecca P Gelber; J Michael Gaziano; E John Orav; Joann E Manson; Julie E Buring; Tobias Kurth Journal: J Am Coll Cardiol Date: 2008-08-19 Impact factor: 24.094
Authors: R Kevin Rogers; Josef Stehlik; Gregory J Stoddard; Thomas Greene; Sean P Collins; W Frank Peacock; Alan D Maisel; Paul Clopton; Andrew D Michaels Journal: Eur J Heart Fail Date: 2009-10-06 Impact factor: 15.534